聚焦成都"两会时间"，翻阅2025年的发展答卷，"很不平凡"成为最贴切的年度写照。 实现地区生产总值2.48万亿元、增长5.8%，经济运行回升向好；社会消费品零售总额增长5.5%，总量居副省级城市第1位，消费引擎强劲发力……这份成绩 单里，既有经济增长的硬核支撑，也有提振消费的务实行动，勾勒出成都高质量发展的清晰脉络。 GDP连跨6个千亿级台阶，这是"硬实力" 消费再跨1个千亿级台阶，这是"实举措" 创新成都的另一面，是烟火成都，消费可谓是其经济的基础盘。 作为"五中心五地"发展定位的重要组成，国际消费中心城市建设始终是成都高质量发展的核心发力点。 2025年，成都消费市场延续稳中有升、量质齐升的良好态势，社会消费品零售总额增长5.5%、总量居副省级城市第1位。这是自2023年跻身万亿级消费城市 以来，成都消费规模再跨1个千亿级台阶，消费能级实现持续跃升。 这一成绩的背后，是成都以系统思维推进国际消费中心城市建设的务实实践，一系列靶向施策的举措为消费增长注入强劲动能。 服务国省大局，成都努力担重任、挑大梁。 2025年，成都规上工业增加值同比增长7.0%，实现"高开高走"，成为经济回升向好的关键底气。 这一年 ...

▲领克汽车成都工厂 工业是实体经济的重要组成部分，也是经济稳定运行的"压舱石"。1月27日，红星新闻记者从成都市经信局市新经济委了解到，2025年成都工业 展现出强大韧性与内生动力，实现规模与效益同步提升，为成都建设全国先进制造业基地奠定了坚实基础。 据介绍，2025年全市规上工业增加值同比增长7.0%，实现"高开高走"。工业投资同比增长19.7%，高技术制造业投资增长23.4%。重点产业链表 现亮眼，人工智能、新型材料等10条制造业产业链营收实现两位数增长。1—11月份，规模以上工业企业营业收入、利润总额分别增长2.4%、 15.7%，工业营收连续跨越3个千亿级台阶。 推动产业集群能级持续跃升 国家级集群数量居副省级城市第二 前不久，工信部公布了2025年度（第四批）中小企业特色产业集群名单，成都共有3个集群新入选。着眼产业生态与梯队建设，成都推动产业集群能级持续 跃升，形成"国家队"与"特色群"协同发展的良好格局。 据介绍，目前成都已培育形成电子信息、装备制造2个万亿级产业集群，5个国家级先进制造业集群、8个国家级中小企业特色产业集群，国家级集群数量居 副省级城市第二。企业培育体系也持续完善，全年新增制造 ...

Core Insights - Rui Jian Pharmaceutical has achieved significant milestones in the development of its Parkinson's disease cell therapy product NouvNeu001, becoming the first globally to receive Fast Track designation from the FDA and entering Phase II clinical trials in China [1][4] - Chengdu High-tech Zone is emerging as a key player in the biopharmaceutical industry, with a focus on innovative drug development and a robust ecosystem supporting various companies [3][12] Company Developments - Rui Jian Pharmaceutical's NouvNeu001 is the first iPSC-derived universal cell therapy for Parkinson's disease to gain Fast Track status from the FDA, while also progressing in clinical trials in China [1] - The company is also advancing other products, such as NouvNeu004 for multiple system atrophy, which has received approval for full-cycle clinical trials in China [4] - Recent funding of over 300 million yuan for Rui Jian Pharmaceutical will accelerate the development of its Parkinson's and ophthalmic treatment products [14] Industry Trends - Chengdu High-tech Zone has been recognized as a leading biopharmaceutical hub, ranking alongside other major innovation districts in China [3] - The region is witnessing a surge in innovative products, with multiple companies achieving significant breakthroughs in various therapeutic areas, including diabetes and cancer [7][5] - The biopharmaceutical industry in Chengdu is projected to exceed 128 billion yuan in scale by 2024, with over 3,000 companies contributing to this growth [7] Ecosystem and Collaboration - The development of Rui Jian Pharmaceutical is closely tied to the supportive ecosystem in Chengdu High-tech Zone, which includes a network of suppliers and clinical resources [8][10] - The establishment of the "Global New Drug Discovery Center" aims to integrate resources from over 3,000 biopharmaceutical companies in the region, enhancing collaboration and innovation [11] - The collaboration between enterprises and institutions, such as Sichuan University West China Hospital, is fostering a comprehensive innovation chain from research to commercialization [12][18] Policy and Financial Support - Chengdu High-tech Zone has implemented supportive policies and established a substantial investment fund to facilitate the growth of the biopharmaceutical sector [16][17] - The "Wutong Plan" provides a comprehensive service framework for biopharmaceutical companies, covering all stages from drug development to market entry [17] - The region's proactive approach in policy-making and capital investment is crucial in overcoming challenges in the biopharmaceutical innovation landscape [16][14]